{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T13:56:07Z","timestamp":1761746167191,"version":"3.41.0"},"reference-count":81,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,4,18]],"date-time":"2025-04-18T00:00:00Z","timestamp":1744934400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,4,18]],"date-time":"2025-04-18T00:00:00Z","timestamp":1744934400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncol Ther"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s40487-025-00339-1","type":"journal-article","created":{"date-parts":[[2025,4,18]],"date-time":"2025-04-18T13:19:27Z","timestamp":1744982367000},"page":"325-338","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Promising Drugs Targeting Specific Mechanisms of Deregulation in T\u00a0Cell Lineage Acute Lymphoblastic Leukemia"],"prefix":"10.1007","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5332-2404","authenticated-orcid":false,"given":"Xavier","family":"Thomas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,18]]},"reference":[{"key":"339_CR1","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1056\/NEJMra1400972","volume":"373","author":"SP Hunger","year":"2015","unstructured":"Hunger SP, Mullighan CG. Acute lymphoblastic leukemia in children. N Engl J Med. 2015;373:1541\u201352.","journal-title":"N Engl J Med"},{"key":"339_CR2","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1182\/blood-2011-03-338707","volume":"118","author":"M Schrappe","year":"2011","unstructured":"Schrappe M, Valsecchi MG, Bartram CR, et al. Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study. Blood. 2011;118:2077\u201384.","journal-title":"Blood"},{"key":"339_CR3","doi-asserted-by":"publisher","first-page":"3739","DOI":"10.1182\/blood-2014-01-547695","volume":"123","author":"K Beldjord","year":"2014","unstructured":"Beldjord K, Chevret S, Asnafi V, et al. Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia. Blood. 2014;123:3739\u201349.","journal-title":"Blood"},{"key":"339_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2016.111","volume":"6","author":"A Desjonqui\u00e8res","year":"2016","unstructured":"Desjonqui\u00e8res A, Chevallier P, Thomas X, et al. Acute lymphoblastic leukemia relapsing after first-line pediatric-inspired therapy: a retrospective GRAALL study. Blood Cancer J. 2016;6:e504.","journal-title":"Blood Cancer J"},{"key":"339_CR5","first-page":"3019","volume":"141","author":"SJ Lim","year":"2023","unstructured":"Lim SJ, Ford JB, Hermiston ML. How I treat newly diagnosed and refractory T-cell acute lymphoblastic lymphoma in children and young adults. Blood. 2023;141:3019\u201330.","journal-title":"Blood"},{"key":"339_CR6","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1038\/ng.3909","volume":"49","author":"Y Liu","year":"2017","unstructured":"Liu Y, Easton J, Shao Y, et al. The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia. Nat Genet. 2017;49:1211\u20138.","journal-title":"Nat Genet"},{"key":"339_CR7","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/S1535-6108(02)00018-1","volume":"1","author":"AA Ferrando","year":"2002","unstructured":"Ferrando AA, Neuberg DS, Staunton J, et al. Gene expression signatures define novel oncogenic pathways in T\u00a0cell acute lymphoblastic leukemia. Cancer Cell. 2002;1:75\u201387.","journal-title":"Cancer Cell"},{"key":"339_CR8","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1080\/13543784.2023.2161361","volume":"32","author":"X Thomas","year":"2023","unstructured":"Thomas X. T-cell acute lymphoblastic leukemia: promising experimental drugs in clinical development. Exp Opin Invest Drugs. 2023;32:37\u201352.","journal-title":"Exp Opin Invest Drugs"},{"key":"339_CR9","first-page":"3352","volume":"55","author":"CU Lambe","year":"1995","unstructured":"Lambe CU, Averett DR, Paff MT, et al. 2-Amino-6-methoxypurine arabinoside: an agent for T-cell malignancies. Cancer Res. 1995;55:3352\u20136.","journal-title":"Cancer Res"},{"key":"339_CR10","doi-asserted-by":"publisher","first-page":"5329","DOI":"10.1158\/1078-0432.CCR-06-0606","volume":"12","author":"MH Cohen","year":"2006","unstructured":"Cohen MH, Johnson JR, Massie T, et al. Approval summary: nelarabine for the treatment of T-cell lymphoblastic leukemia\/lymphoma. Clin Cancer Res. 2006;12:5329\u201335.","journal-title":"Clin Cancer Res"},{"key":"339_CR11","doi-asserted-by":"publisher","first-page":"3396","DOI":"10.1200\/JCO.2005.03.199","volume":"23","author":"J Kurtzberg","year":"2005","unstructured":"Kurtzberg J, Ernst TJ, Keating MJ, et al. Phase\u00a0I study of 506U78 administered on a consecutive 5-day schedule in children and adults with refractory malignancies. J Clin Oncol. 2005;23:3396\u2013403.","journal-title":"J Clin Oncol"},{"key":"339_CR12","doi-asserted-by":"publisher","first-page":"3376","DOI":"10.1200\/JCO.2005.03.426","volume":"23","author":"SL Berg","year":"2005","unstructured":"Berg SL, Blaney SM, Devidas M, et al. Phase\u00a0II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the Children\u2019s Oncology Group. J Clin Oncol. 2005;23:3376\u201382.","journal-title":"J Clin Oncol"},{"key":"339_CR13","doi-asserted-by":"publisher","first-page":"5136","DOI":"10.1182\/blood-2006-11-056754","volume":"109","author":"DJ DeAngelo","year":"2007","unstructured":"DeAngelo DJ, Yu D, Johnson JL, et al. Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801. Blood. 2007;109:5136\u201342.","journal-title":"Blood"},{"key":"339_CR14","doi-asserted-by":"publisher","first-page":"3504","DOI":"10.1182\/blood-2011-01-329441","volume":"118","author":"N G\u00f6kbuget","year":"2011","unstructured":"G\u00f6kbuget N, Basara N, Baurmann H, et al. High single-drug activity of nelarabine in relapsed T-lymphoblastic leukemia\/lymphoma offers curative option with subsequent stem cell transplantation. Blood. 2011;118:3504\u201311.","journal-title":"Blood"},{"key":"339_CR15","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.1200\/JCO.2011.40.8724","volume":"30","author":"KP Dunsmore","year":"2012","unstructured":"Dunsmore KP, Devidas M, Linda SB, et al. Pilot study of nelarabine in combination with intensive chemotherapy in high-risk T-cell acute lymphoblastic leukemia: a report from the Children\u2019s Oncology Group. J Clin Oncol. 2012;30:2753\u20139.","journal-title":"J Clin Oncol"},{"key":"339_CR16","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1002\/pbc.25470","volume":"62","author":"SS Winter","year":"2015","unstructured":"Winter SS, Dunsmore KP, Devidas M, et al. Safe integration of nelarabine into intensive chemotherapy in newly diagnosed T-cell acute lymphoblastic leukemia: Children\u2019s Oncology Group Study AALL0434. Pediatr Blood Cancer. 2015;62:1176\u201383.","journal-title":"Pediatr Blood Cancer"},{"key":"339_CR17","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1038\/leu.2013.312","volume":"28","author":"P Jain","year":"2014","unstructured":"Jain P, Kantarjian H, Ravandi F, et al. The combination of hyper-CVAD plus nelarabine as frontline therapy in adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma: MD Anderson Cancer Center experience. Leukemia. 2014;28:973\u20135.","journal-title":"Leukemia"},{"key":"339_CR18","doi-asserted-by":"crossref","unstructured":"Rowntree CJ, Kirkwood AA, Clifton-Hadley L, et al. First analysis of the UKALL 14 randomized trial to determine whether the addition of nelarabine to standard chemotherapy improves event free survival in adults with T-cell acute lymphoblastic leukaemia (CRUK\/09\/006). In: Annual Meeting of the American Society of Hematology 2021; abstract 366.","DOI":"10.1182\/blood-2021-152355"},{"key":"339_CR19","doi-asserted-by":"publisher","first-page":"4239","DOI":"10.1182\/blood.V118.21.4239.4239","volume":"118","author":"T Kadia","year":"2011","unstructured":"Kadia T, Gandhi V, Thomas DA, et al. Phase\u00a0I study of continuous-infusion nelarabine in patients with advanced lymphoid malignancies. Blood. 2011;118:4239.","journal-title":"Blood"},{"key":"339_CR20","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1158\/1078-0432.CCR-15-2869","volume":"23","author":"Y Pikman","year":"2017","unstructured":"Pikman Y, Alexe G, Roti G, et al. Synergistic drug combinations with CDK4\/6 inhibitor in T-cell acute lymphoblastic leukemia. Clin Cancer Res. 2017;23:1012\u201324.","journal-title":"Clin Cancer Res"},{"key":"339_CR21","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.ccr.2012.09.016","volume":"22","author":"CM Sawai","year":"2012","unstructured":"Sawai CM, Freund J, Oh P, et al. Therapeutic targeting of the cyclin D3: CDK4\/6 complex in T\u00a0cell leukemia. Cancer Cell. 2012;22:452\u201365.","journal-title":"Cancer Cell"},{"key":"339_CR22","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/nature13393","volume":"511","author":"N Kwiatkowski","year":"2014","unstructured":"Kwiatkowski N, Zhang T, Rahl PB, et al. Targeting transcription regulation in cancer with a covalent CDK7 inhibitor. Nature. 2014;511:616\u201320.","journal-title":"Nature"},{"key":"339_CR23","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1007\/s00280-013-2249-z","volume":"72","author":"I Gojo","year":"2013","unstructured":"Gojo I, Sadowska M, Walker A, et al. Clinical and laboratory studies of the novel cyclin-dependent kinase inhibitor dinaciclib (SCH727965) in acute leukemias. Cancer Chemother Pharmacol. 2013;72:897\u2013908.","journal-title":"Cancer Chemother Pharmacol"},{"key":"339_CR24","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1038\/nchembio.2538","volume":"14","author":"CM Olson","year":"2018","unstructured":"Olson CM, Jiang B, Erb MA, et al. Pharmacological perturbation of CDK9 using selective CDK9 inhibition or degradation. Nat Chem Biol. 2018;14:163\u201370.","journal-title":"Nat Chem Biol"},{"key":"339_CR25","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1158\/1078-0432.CCR-19-1853","volume":"26","author":"J Cidado","year":"2020","unstructured":"Cidado J, Boiko S, Proia T, et al. AZD4573 is a highly selective CDK9 inhibitor that suppresses MCL-1 and induces apoptosis in hematologic cancer cells. Clin Cancer Res. 2020;26:922\u201334.","journal-title":"Clin Cancer Res"},{"key":"339_CR26","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1182\/blood.2022017755","volume":"141","author":"M Simonin","year":"2023","unstructured":"Simonin M, Schmidt A, Bontoux C, et al. Prognostic value and oncogenic landscape of TP53 alterations in adult and pediatric T-ALL. Blood. 2023;141:1353\u20138.","journal-title":"Blood"},{"key":"339_CR27","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/nrc.2017.109","volume":"18","author":"VJN Bykov","year":"2018","unstructured":"Bykov VJN, Eriksson SE, Bianchi J, et al. Targeting mutant p53 for efficient cancer therapy. Nat Rev Cancer. 2018;18:89\u2013102.","journal-title":"Nat Rev Cancer"},{"key":"339_CR28","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1038\/s41375-019-0685-4","volume":"34","author":"R Kim","year":"2020","unstructured":"Kim R, Boissel N, Touzart A, et al. Adult T-cell acute lymphoblastic leukemias with IL7R pathway mutations are slow-responders who do not benefit from allogeneic stem cell transplantation. Leukemia. 2020;34:1730\u201340.","journal-title":"Leukemia"},{"key":"339_CR29","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1182\/blood.2019003880","volume":"135","author":"R De Smedt","year":"2020","unstructured":"De Smedt R, Morscio J, Reunes L, et al. Targeting cytokine- and therapy-induced PIM1 activation in preclinical models of T-cell acute lymphoblastic leukemia and lymphoma. Blood. 2020;135:1685\u201395.","journal-title":"Blood"},{"key":"339_CR30","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1182\/blood-2014-06-580480","volume":"125","author":"SL Maude","year":"2015","unstructured":"Maude SL, Dolai S, Delgado-Martin C, et al. Efficacy of JAK\/STAT pathway inhibition in murine xenograft models of early T-cell precursor (ETP) acute lymphoblastic leukemia. Blood. 2015;125:1759\u201367.","journal-title":"Blood"},{"key":"339_CR31","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000310","volume":"3","author":"D Verbeke","year":"2019","unstructured":"Verbeke D, Gielen O, Jacobs K, et al. Ruxolitinib synergizes with dexamethasone for the treatment of T-cell acute lymphoblastic leukemia. Hemasphere. 2019;3: e310.","journal-title":"Hemasphere"},{"key":"339_CR32","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1038\/s41375-022-01558-5","volume":"36","author":"K Bodaar","year":"2022","unstructured":"Bodaar K, Yamagata N, Barthe A, et al. JAK3 mutations and mitochondrial apoptosis resistance in T-cell acute lymphoblastic leukemia. Leukemia. 2022;36:1499\u2013507.","journal-title":"Leukemia"},{"key":"339_CR33","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1038\/leu.2017.276","volume":"32","author":"S Degryse","year":"2018","unstructured":"Degryse S, de Bock CE, Demeyer S, et al. Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK\/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia. Leukemia. 2018;32:788\u2013800.","journal-title":"Leukemia"},{"key":"339_CR34","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1038\/leu.2008.80","volume":"22","author":"A Quintas-Cardama","year":"2008","unstructured":"Quintas-Cardama A, Tong W, Manshouri T, et al. Activity of tyrosine kinase inhibitors against human NUP214-ABL1-positive T\u00a0cell malignancies. Leukemia. 2008;22:1117\u201324.","journal-title":"Leukemia"},{"key":"339_CR35","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1038\/leu.2008.278","volume":"23","author":"C Graux","year":"2009","unstructured":"Graux C, Stevens-Kroef M, Lafage M, et al. Heterogeneous patterns of amplification of the NUP214-ABL1 fusion gene in T-cell acute lymphoblastic leukemia. Leukemia. 2009;23:125\u201333.","journal-title":"Leukemia"},{"key":"339_CR36","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1073\/pnas.1717125115","volume":"115","author":"B Chen","year":"2018","unstructured":"Chen B, Jiang L, Zhong ML, et al. Identification of fusion genes and characterization of transcriptome features in T-cell acute lymphoblastic leukemia. Proc Natl Acad Sci USA. 2018;115:373\u20138.","journal-title":"Proc Natl Acad Sci USA"},{"key":"339_CR37","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1038\/s43018-020-00167-4","volume":"2","author":"Y Gocho","year":"2021","unstructured":"Gocho Y, Liu J, Hu J, et al. Network-based systems pharmacology reveals heterogeneity in LCK and BCL2 signaling and therapeutic sensitivity of T-cell acute lymphoblastic leukemia. Nat Cancer. 2021;2:284\u201399.","journal-title":"Nat Cancer"},{"key":"339_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbior.2019.100647","volume":"74","author":"JCG Van der Zwet","year":"2019","unstructured":"Van der Zwet JCG, Cordo V, Cant\u00e9-Barrett K, Meijerink JPP. Multi-omic approaches to improve outcome for T-cell acute lymphoblastic leukemia patients. Adv Biol Reg. 2019;74:100647.","journal-title":"Adv Biol Reg"},{"key":"339_CR39","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1182\/blood-2009-02-206722","volume":"114","author":"A Gutierrez","year":"2009","unstructured":"Gutierrez A, Sanda T, Grebliunaite R, et al. High frequency of PTEN, Pl3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia. Blood. 2009;114:647\u201350.","journal-title":"Blood"},{"key":"339_CR40","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1016\/j.ccr.2013.10.022","volume":"24","author":"E Piovan","year":"2013","unstructured":"Piovan E, Yu J, Tosello V, et al. Direct reversal of glucocorticoid resistance by AKT inhibition in acute lymphoblastic leukemia. Cancer Cell. 2013;24:766\u201376.","journal-title":"Cancer Cell"},{"key":"339_CR41","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.exphem.2011.01.005","volume":"39","author":"A Batista","year":"2011","unstructured":"Batista A, Barata JT, Raderschall E, et al. Targeting of active mTOR inhibits primary leukemia T\u00a0cells and synergizes with cytotoxic drugs and signaling inhibitors. Exp Hematol. 2011;39:457\u201372.","journal-title":"Exp Hematol"},{"key":"339_CR42","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1038\/leu.2012.285","volume":"27","author":"C Shepherd","year":"2013","unstructured":"Shepherd C, Banerjee L, Cheung CW, et al. Pl3K\/mTOR inhibition upregulates NOTCH-MYC signaling leading to an impaired cytotoxic response. Leukemia. 2013;27:650\u201360.","journal-title":"Leukemia"},{"key":"339_CR43","first-page":"2704","volume":"21","author":"N Daver","year":"2015","unstructured":"Daver N, Boumber Y, Kantarjian H, et al. A phase\u00a0I\/II study of the mTOR inhibitor everolimus in combination with HyperCVAD chemotherapy in patients with relapsed\/refractory acute lymphoblastic leukemia. Cancer Res. 2015;21:2704\u201314.","journal-title":"Cancer Res"},{"key":"339_CR44","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1038\/leu.2012.136","volume":"26","author":"C Simioni","year":"2012","unstructured":"Simioni C, Neri LM, Tabellini G, et al. Cytotoxic activity of the novel Akt inhibitor, MK-2206, in T-cell acute lymphoblastic leukemia. Leukemia. 2012;26:2336\u201342.","journal-title":"Leukemia"},{"key":"339_CR45","doi-asserted-by":"publisher","first-page":"22128","DOI":"10.18632\/oncotarget.8031","volume":"7","author":"JT Lynch","year":"2016","unstructured":"Lynch JT, McEwen R, Crafter C, et al. Identification of differential Pl3K pathway target dependencies in T-cell acute lymphoblastic leukemia through a large cancer cell panel screen. Oncotarget. 2016;7:22128\u201339.","journal-title":"Oncotarget"},{"key":"339_CR46","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1182\/blood-2023-186699","volume":"142","author":"L Courtois","year":"2023","unstructured":"Courtois L, Cabannes-Hamy A, Kim R, et al. IL-7 receptor expression is frequent in T-cell acute lymphoblastic leukemia and predicts sensitivity to JAK-inhibition. Blood. 2023;142:158\u201371.","journal-title":"Blood"},{"key":"339_CR47","doi-asserted-by":"publisher","first-page":"4333","DOI":"10.1200\/JCO.2012.48.5292","volume":"31","author":"A Trinquand","year":"2013","unstructured":"Trinquand A, Tanguy-Schmidt A, Ben Abdelali R, et al. Toward a NOTCH1\/FBXW7\/RAS\/PTEN-based oncogenetic risk classification of adult T-cell acute lymphoblastic leukemia: a Group for Research in Adult Acute Lymphoblastic Leukemia study. J Clin Oncol. 2013;31:4333\u201342.","journal-title":"J Clin Oncol"},{"key":"339_CR48","doi-asserted-by":"publisher","first-page":"3394","DOI":"10.1038\/s41375-021-01291-5","volume":"35","author":"JCG Van der Zwet","year":"2021","unstructured":"Van der Zwet JCG, Buijs-Gladdines JGCAM, Cordo V, et al. MAPK-ERK is a central pathway in T-cell acute lymphoblastic leukemia that drives steroid resistance. Leukemia. 2021;35:3394\u2013405.","journal-title":"Leukemia"},{"key":"339_CR49","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-059872","volume":"12","author":"T Menne","year":"2022","unstructured":"Menne T, Slade D, Savage J, et al. Selumetinib in combination with dexamethasone for the treatment of relapsed\/refractory RAS-pathway mutated paediatric and adult acute lymphoblastic leukaemia (SeluDex): study protocol for an international, parallel-group, dose-finding with expansion phase\u00a0I\/II trial. BMJ Open. 2022;12: e059872.","journal-title":"BMJ Open"},{"key":"339_CR50","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1158\/2159-8290.CD-14-0353","volume":"4","author":"TN Chonghaile","year":"2014","unstructured":"Chonghaile TN, Roderick JE, Glenfield C, et al. Maturation stage of T-cell acute lymphoblastic leukemia determines BCL-2 versus BCL-XL dependence and sensitivity to ABT-199. Cancer Discov. 2014;4:1074\u201387.","journal-title":"Cancer Discov"},{"key":"339_CR51","doi-asserted-by":"publisher","first-page":"3738","DOI":"10.1182\/blood-2014-05-574566","volume":"124","author":"S Piers","year":"2014","unstructured":"Piers S, Matthijssens F, Goossens S, et al. ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia. Blood. 2014;124:3738\u201347.","journal-title":"Blood"},{"key":"339_CR52","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.clml.2019.09.608","volume":"20","author":"G Richard-Carpentier","year":"2020","unstructured":"Richard-Carpentier G, Jabbour E, Short NJ, et al. Clinical experience with venetoclax combined with chemotherapy for relapsed or refractory T-cell acute lymphoblastic leukemia. Clin Lymphoma Myeloma Leuk. 2020;20:212\u20138.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"339_CR53","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1158\/2159-8290.CD-20-1465","volume":"11","author":"VA Pullarkat","year":"2021","unstructured":"Pullarkat VA, Lacayo NJ, Jabbour E, et al. Venetoclax and navitoclax in combination with chemotherapy in patients with relapsed or refractory acute lymphoblastic leukemia and lymphoblastic lymphoma. Cancer Discov. 2021;11:1440\u201353.","journal-title":"Cancer Discov"},{"key":"339_CR54","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1038\/s41375-018-0201-2","volume":"33","author":"Z Li","year":"2019","unstructured":"Li Z, He S, Look AT. The MCL1-specific inhibitor S63845 acts synergistically with venetoclax\/ABT-199 to induce apoptosis in T-cell acute lymphoblastic leukemia cells. Leukemia. 2019;33:262\u20136.","journal-title":"Leukemia"},{"key":"339_CR55","doi-asserted-by":"publisher","first-page":"eabc4834","DOI":"10.1126\/scitranslmed.abc4834","volume":"13","author":"A Touzart","year":"2021","unstructured":"Touzart A, Mayakonda A, Smith C, et al. Epigenetic analysis of patients with T-ALL identifies poor outcomes and a hypomethylating agent-responsive subgroup. Sci Transl Med. 2021;13:eabc4834.","journal-title":"Sci Transl Med"},{"issue":"Suppl. 1","key":"339_CR56","doi-asserted-by":"publisher","first-page":"6174","DOI":"10.1182\/blood-2023-189776","volume":"142","author":"A Kamiunten","year":"2023","unstructured":"Kamiunten A. Clinical outcomes of tucidinostat therapy for relapsed\/refractory adult T-cell leukemia-lymphoma (ATL) in clinical practice. Blood. 2023;142(Suppl. 1):6174.","journal-title":"Blood"},{"key":"339_CR57","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1038\/leu.2012.31","volume":"26","author":"A Vilas-Zornoza","year":"2012","unstructured":"Vilas-Zornoza A, Agirre X, Abizanda G, et al. Preclinical activity of LBH589 alone or in combination with chemotherapy in a xenogeneic mouse model of human acute lymphoblastic leukemia. Leukemia. 2012;26:1517\u201326.","journal-title":"Leukemia"},{"key":"339_CR58","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1080\/10428194.2019.1691195","volume":"61","author":"W Guan","year":"2020","unstructured":"Guan W, Jing Y, Dou L, et al. Chidamide in combination with chemotherapy in refractory and relapsed T lymphoblastic lymphoma\/leukemia. Leuk Lymphoma. 2020;61:855\u201361.","journal-title":"Leuk Lymphoma"},{"key":"339_CR59","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.3109\/10428194.2015.1110747","volume":"57","author":"BY Lu","year":"2016","unstructured":"Lu BY, Thanawala SU, Zochowski KC, et al. Decitabine enhances chemosensitivity of early T-cell precursor acute lymphoblastic leukemia cell lines and patient-derived samples. Leuk Lymphoma. 2016;57:1938\u201341.","journal-title":"Leuk Lymphoma"},{"key":"339_CR60","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.hemonc.2019.10.002","volume":"14","author":"N Farhadfar","year":"2021","unstructured":"Farhadfar N, Li Y, May WS, Adams CB. Venetoclax and decitabine for treatment of relapsed T-cell acute lymphoblastic leukemia: a case report and review of literature. Hematol Oncol Stem Cell Ther. 2021;14:246\u201351.","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"339_CR61","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1002\/hon.2783","volume":"38","author":"T Meng","year":"2020","unstructured":"Meng T, Yao Y, Xu Y, et al. Salvage therapy with decitabine in combination with granulocyte colony-stimulating factor, low-dose cytarabine, and aclarubicin in patients with refractory or relapsed early T-cell precursor acute lymphoblastic leukemia. Hematol Oncol. 2020;38:834\u20137.","journal-title":"Hematol Oncol"},{"key":"339_CR62","doi-asserted-by":"publisher","first-page":"3300","DOI":"10.1080\/10428194.2021.1957876","volume":"62","author":"CL Wan","year":"2021","unstructured":"Wan CL, Zou JY, Qiao M, et al. Venetoclax combined with azacitidine as an effective and safe salvage regimen for relapsed or refractory T-cell acute lymphoblastic leukemia: a case series. Leuk Lymphoma. 2021;62:3300\u20133.","journal-title":"Leuk Lymphoma"},{"key":"339_CR63","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1038\/nature09504","volume":"468","author":"P Filippakopoulos","year":"2010","unstructured":"Filippakopoulos P, Qi J, Picaud S, et al. Selective inhibition of BET bromodomains. Nature. 2010;468:1067\u201373.","journal-title":"Nature"},{"key":"339_CR64","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1182\/blood-2013-08-522698","volume":"123","author":"JE Roderick","year":"2014","unstructured":"Roderick JE, Tesell J, Shultz LD, et al. c-Myc inhibition prevents leukemia initiation in mice and impairs the growth of relapsed and induction failure pediatric T-ALL cells. Blood. 2014;123:1040\u201350.","journal-title":"Blood"},{"key":"339_CR65","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1038\/leu.2017.10","volume":"31","author":"S Peirs","year":"2017","unstructured":"Peirs S, Frismantas V, Marthijssens F, et al. Targeting BET proteins improves the therapeutic efficacy of BCL-2 inhibition in T-cell acute lymphoblastic leukemia. Leukemia. 2017;31:2037\u201347.","journal-title":"Leukemia"},{"key":"339_CR66","doi-asserted-by":"publisher","first-page":"2843","DOI":"10.1182\/blood-2012-02-413021","volume":"120","author":"CJ Ott","year":"2012","unstructured":"Ott CJ, Kopp N, Bird L, et al. BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia. Blood. 2012;120:2843\u201352.","journal-title":"Blood"},{"key":"339_CR67","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1158\/2643-3230.BCD-20-0026","volume":"1","author":"AC McCarter","year":"2020","unstructured":"McCarter AC, Gatta GD, Melnick A, et al. Combinatorial ETS1-dependent control of oncogenic NOTCH1 enhancers in T-cell leukemia. Blood Cancer Discov. 2020;1:178\u201397.","journal-title":"Blood Cancer Discov"},{"key":"339_CR68","doi-asserted-by":"publisher","first-page":"3067","DOI":"10.1080\/10428194.2019.1617860","volume":"60","author":"L Astorgues-Xerri","year":"2019","unstructured":"Astorgues-Xerri L, Vasquez R, Odore E, et al. Insights into the cellular pharmacological properties of the BET-inhibitor OTX015\/MK-8628 (birabresib), alone and in combination, in leukemia models. Leuk Lymphoma. 2019;60:3067\u201370.","journal-title":"Leuk Lymphoma"},{"key":"339_CR69","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1126\/science.1102160","volume":"306","author":"AP Weng","year":"2004","unstructured":"Weng AP, Ferrando AA, Lee W, et al. Activating mutations of NOTCH1 in human T\u00a0cell acute lymphoblastic leukemia. Science. 2004;306:269\u201371.","journal-title":"Science"},{"key":"339_CR70","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1084\/jem.20070876","volume":"204","author":"J O\u2019Neil","year":"2007","unstructured":"O\u2019Neil J, Grim J, Strack P, et al. FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gamma-secretase inhibitors. J Exp Med. 2007;204:1813\u201324.","journal-title":"J Exp Med"},{"key":"339_CR71","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.pharmthera.2013.09.005","volume":"141","author":"N Takebe","year":"2014","unstructured":"Takebe N, Nguyen D, Yang SX. Targeting notch signaling pathway in cancer: clinical development advances and challenges. Pharmacol Ther. 2014;141:140\u20139.","journal-title":"Pharmacol Ther"},{"key":"339_CR72","doi-asserted-by":"publisher","first-page":"eaau6246","DOI":"10.1126\/scitranslmed.aau6246","volume":"11","author":"RA Habets","year":"2019","unstructured":"Habets RA, de Bock CE, Serneels L, et al. Safe targeting of T\u00a0cell acute lymphoblastic leukemia by pathology-specific NOTCH inhibition. Sci Transl Med. 2019;11:eaau6246.","journal-title":"Sci Transl Med"},{"key":"339_CR73","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1038\/nature08543","volume":"462","author":"RE Moellering","year":"2009","unstructured":"Moellering RE, Cornejo M, Davis TN, et al. Direct inhibition of the NOTCH transcription factor complex. Nature. 2009;462:182\u20138.","journal-title":"Nature"},{"key":"339_CR74","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1038\/leu.2013.366","volume":"28","author":"D Koyama","year":"2014","unstructured":"Koyama D, Kikuchi J, Hiraoka N, et al. Proteasome inhibitors exert cytotoxicity and increase chemosensitivity via transcriptional repression of Notch1 in T-cell acute lymphoblastic leukemia. Leukemia. 2014;28:1216\u201326.","journal-title":"Leukemia"},{"key":"339_CR75","doi-asserted-by":"publisher","first-page":"8242","DOI":"10.1073\/pnas.112218799","volume":"99","author":"H Mori","year":"2002","unstructured":"Mori H, Colman SM, Xiao Z, et al. Chromosome translocations and covert leukemic clones are generated during normal fetal development. Proc Natl Acad Sci USA. 2002;99:8242\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"key":"339_CR76","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1038\/s41586-023-05812-3","volume":"615","author":"GC Issa","year":"2023","unstructured":"Issa GC, Aldoss I, DiPersio J, et al. The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia. Nature. 2023;615:920\u20134.","journal-title":"Nature"},{"key":"339_CR77","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.00826","author":"GC Issa","year":"2024","unstructured":"Issa GC, Aldoss I, Thirman MJ, et al. Menin inhibition with revumenib for KMT2A-rearranged relapsed or refractory acute leukemia (AUGMENT-101). J Clin Oncol. 2024. https:\/\/doi.org\/10.1200\/JCO.24.00826.","journal-title":"J Clin Oncol"},{"key":"339_CR78","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s40487-024-00262-x","volume":"12","author":"X Thomas","year":"2024","unstructured":"Thomas X. Small molecule menin inhibitors: novel therapeutic agents targeting acute myeloid leukemia with KMT2A rearrangement or NPM1 mutation. Oncol Ther. 2024;12:57\u201372.","journal-title":"Oncol Ther"},{"key":"339_CR79","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.3324\/haematol.2022.281583","volume":"108","author":"C Smith","year":"2023","unstructured":"Smith C, Goyal A, Weichenhan D, et al. TAL1 activation in T-cell acute lymphoblastic leukemia: a novel oncogenic 3\u2019 neo-enhancer. Haematologica. 2023;108:1259\u201371.","journal-title":"Haematologica"},{"key":"339_CR80","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1038\/leu.2017.317","volume":"32","author":"V Walf-Vorderw\u00fclbecke","year":"2018","unstructured":"Walf-Vorderw\u00fclbecke V, Pearce K, Brooks T, et al. Targeting acute myeloid leukemia by drug-induced c-MYB degradation. Leukemia. 2018;32:882\u20139.","journal-title":"Leukemia"},{"key":"339_CR81","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s12943-022-01701-x","volume":"22","author":"C Smith","year":"2023","unstructured":"Smith C, Touzart A, Simonin M, et al. Harnessing the MYB-dependent TAL1 5\u2019super-enhancer for targeted therapy in T-ALL. Mol Cancer. 2023;22:12.","journal-title":"Mol Cancer"}],"container-title":["Oncology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40487-025-00339-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40487-025-00339-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40487-025-00339-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T14:03:51Z","timestamp":1748873031000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40487-025-00339-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,18]]},"references-count":81,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["339"],"URL":"https:\/\/doi.org\/10.1007\/s40487-025-00339-1","relation":{},"ISSN":["2366-1070","2366-1089"],"issn-type":[{"type":"print","value":"2366-1070"},{"type":"electronic","value":"2366-1089"}],"subject":[],"published":{"date-parts":[[2025,4,18]]},"assertion":[{"value":"7 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Xavier Thomas has nothing to disclose. Xavier Thomas is an editorial board member of Oncology and Therapy. Xavier Thomas was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by the author.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}